HTFL
Heartflow, Inc.
$28.45
+1.25%
$2.5B
No data for this timeframe.
Vol
Market Cap$2.5B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders7 funds
Inst. Value$196.6M
Inst. Activity4 buys / 0 sells
Insider Activity0B / 15S
Insider Net $-$121.3M
SEC Reports7
Press Releases1
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001464521·Prev Close $28.10
Recent Activity
May 20, 2026
SEC
Heartflow's CMO and CEO sold a combined $918K in open-market sales within a week of the company's strong Q1 earnings bea
CLUSTER — Impact 5/10
May 18, 2026
Insider
Rogers Campbell sold 9,219 shares
Chief Medical Officer @ $19.00 ($175.2K)
May 18, 2026
Insider
Rogers Campbell sold 9,219 shares
Chief Medical Officer @ $28.34 ($261.3K)
May 18, 2026
Insider
Rogers Campbell sold 9,219 shares
Chief Medical Officer @ $0.00 ($0.00)
May 15, 2026
short_volume
Short Volume: HTFL — 63.6% short (0.6M / 0.9M)
Short: 599,174 | Exempt: 12,591 | TRF Vol: 941,767 | Short Ratio: 63.6% | Off-exchange volume (dark
May 14, 2026
SEC
Heartflow reported Q1 2026 revenue of $52.6M (+41% YoY), beating the $49.7M consensus, and raised full-year 2026 revenue
8-K — Impact 7/10
May 14, 2026
SEC
Heartflow reported Q1 2026 revenue of $52.6M (+41% YoY), beating the $49.7M consensus, and non-GAAP EPS of -$0.16, beati
PRESS-RELEASE — Impact 7/10
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — ADD
153,346 shares ($4.5M)
Price Targets
$37.00
+29.1% upside
Strong Buy
Current $28.67
Low $35.00
Median $37.00
High $40.00
6 analysts
$35.00
$40.00
Analyst Ratings
4Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 15, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 4, 2026 | William Blair | INITIATE | Outperform |
| Mar 19, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Mar 19, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.13 | $-0.15 — $-0.12 | 88% YoY | 7 |
| Next Q | $-0.11 ▼ -2.7% | $-0.13 — $-0.09 | 59% YoY | 7 |
| Current FY | $-0.49 ▲ +4.8% | $-0.55 — $-0.45 | 70% YoY | 7 |
| Next FY | $-0.26 ▲ +11.9% | $-0.45 — $-0.07 | 46% YoY | 7 |
Latest Reports
MIXED
CLUSTER
5/10
Heartflow's CMO and CEO sold a combined $918K in open-market sales within a week of the company's strong Q1 earnings bea
May 20, 2026
BULLISH
8-K
7/10
Heartflow reported Q1 2026 revenue of $52.6M (+41% YoY), beating the $49.7M consensus, and raised full-year 2026 revenue
May 14, 2026
NEUTRAL
Press
4/10
Heartflow reported its Q4 and full-year 2025 financial results, marking a routine earnings release with no additional gu
Mar 18, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $120.2M | NEW |
| VANGUARD GROUP INC | $46.1M | NEW |
| MORGAN STANLEY | $21.7M | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $4.5M | ADD |
| BANK OF AMERICA CORP | $2.5M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Rogers Campbell | M | $175.2K |
| May 18, 2026 | Rogers Campbell | SELL | $261.3K |
| May 18, 2026 | Rogers Campbell | M | $0.00 |
| May 11, 2026 | Farquhar John | SELL | $657.0K |
| May 7, 2026 | Farquhar John | F | $57.1K |
7 institutional holders with $196.6M total value (6,745,662 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 4,122,853 | $120.2M | 61.1% | NEW |
| 2 | VANGUARD GROUP INC | 1,580,313 | $46.1M | 23.4% | NEW |
| 3 | MORGAN STANLEY | 745,924 | $21.7M | 11.1% | NEW |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 153,346 | $4.5M | 2.3% | ADD +51.0% |
| 5 | BANK OF AMERICA CORP /DE/ | 86,738 | $2.5M | 1.3% | ADD +33.5% |
| 6 | NORGES BANK | 35,000 | $1.0M | 0.5% | NEW |
| 7 | WELLS FARGO & COMPANY/MN | 21,488 | $626.4K | 0.3% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 101,585 | 153,346 | +51.0% | $4.5M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 64,981 | 86,738 | +33.5% | $2.5M | 2025-Q4 |
| NORGES BANK | NEW | — | 35,000 | — | $1.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | NEW | — | 21,488 | — | $626.4K | 2025-Q4 |
| FMR LLC | NEW | — | 4,730,234 | — | $159.2M | 2025-Q3 |
| VANGUARD GROUP INC | NEW | — | 1,451,913 | — | $48.9M | 2025-Q3 |
| MORGAN STANLEY | NEW | — | 755,141 | — | $25.4M | 2025-Q3 |
| UBS Group AG | NEW | — | 152,412 | — | $5.1M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 101,585 | — | $3.4M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 64,981 | — | $2.2M | 2025-Q3 |
9 unique insiders with 15 transactions. Net insider value: -$121.3M ($0.00 bought, $121.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Rogers Campbell | Chief Medical Officer | M | 9,219 | $19.00 | $175.2K |
| May 18, 2026 | Rogers Campbell | Chief Medical Officer | SELL | 9,219 | $28.34 | $261.3K |
| May 18, 2026 | Rogers Campbell | Chief Medical Officer | M | 9,219 | $0.00 | $0.00 |
| May 11, 2026 | Farquhar John C.M. | Chief Executive Officer | SELL | 22,562 | $29.12 | $657.0K |
| May 7, 2026 | Farquhar John C.M. | Chief Executive Officer | F | 1,904 | $29.98 | $57.1K |
| May 7, 2026 | Verghese Vikram | Chief Financial Officer | F | 473 | $29.98 | $14.2K |
| May 7, 2026 | Rogers Campbell | Chief Medical Officer | F | 637 | $29.98 | $19.1K |
| May 7, 2026 | Jones Marie L. | Chief Accounting Officer | F | 82 | $29.98 | $2.5K |
| May 6, 2026 | Jones Marie L. | Chief Accounting Officer | F | 485 | $30.29 | $14.7K |
| May 6, 2026 | Rogers Campbell | Chief Medical Officer | F | 1,634 | $30.29 | $49.5K |
| May 6, 2026 | Verghese Vikram | Chief Financial Officer | F | 1,536 | $30.29 | $46.5K |
| May 6, 2026 | Farquhar John C.M. | Chief Executive Officer | F | 5,300 | $30.29 | $160.5K |
| Apr 30, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | SELL | 892,533 | $29.18 | $26.0M |
| Apr 29, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | SELL | 797,133 | $29.37 | $23.4M |
| Apr 28, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | SELL | 254,110 | $30.51 | $7.8M |
| Apr 10, 2026 | Farquhar John C.M. | Chief Executive Officer | SELL | 22,562 | $26.72 | $602.9K |
| Apr 1, 2026 | Rogers Campbell | Chief Medical Officer | M | 291 | $8.33 | $2.4K |
| Apr 1, 2026 | Rogers Campbell | Chief Medical Officer | M | 291 | $0.00 | $0.00 |
| Apr 1, 2026 | Rogers Campbell | Chief Medical Officer | SELL | 64,533 | $24.64 | $1.6M |
| Apr 1, 2026 | Rogers Campbell | Chief Medical Officer | M | 6,849 | $0.00 | $0.00 |
| Mar 24, 2026 | Lightcap Jeffrey C | Director | J | 206,261 | $0.00 | $0.00 |
| Mar 24, 2026 | HealthCor Partners Management LP | Director | J | 4,615,542 | $0.00 | $0.00 |
| Mar 19, 2026 | Rogers Campbell | Chief Medical Officer | M | 19,402 | $2.22 | $43.1K |
| Mar 19, 2026 | Rogers Campbell | Chief Medical Officer | SELL | 64,533 | $25.69 | $1.7M |
| Mar 19, 2026 | Rogers Campbell | Chief Medical Officer | M | 19,402 | $0.00 | $0.00 |
| Mar 18, 2026 | Farquhar John C.M. | Chief Executive Officer | SELL | 9,725 | $25.00 | $243.1K |
| Mar 11, 2026 | BARABE TIMOTHY C | Director | M | 8,667 | $2.22 | $19.2K |
| Mar 11, 2026 | BARABE TIMOTHY C | Director | M | 8,667 | $0.00 | $0.00 |
| Mar 10, 2026 | Farquhar John C.M. | Chief Executive Officer | SELL | 12,837 | $22.66 | $290.9K |
| Mar 6, 2026 | Farquhar John C.M. | Chief Executive Officer | A | 2,631 | $16.15 | $42.5K |
| Mar 5, 2026 | Cullivan Julie A | Director | SELL | 9,122 | $25.00 | $228.1K |
| Feb 12, 2026 | Rogers Campbell | Chief Medical Officer | M | 19,401 | $2.22 | $43.1K |
| Feb 12, 2026 | Rogers Campbell | Chief Medical Officer | SELL | 65,153 | $24.49 | $1.6M |
| Feb 12, 2026 | Rogers Campbell | Chief Medical Officer | M | 39,709 | $0.00 | $0.00 |
| Feb 10, 2026 | Farquhar John C.M. | Chief Executive Officer | SELL | 22,562 | $27.46 | $619.6K |
| Feb 6, 2026 | Farquhar John C.M. | Chief Executive Officer | A | 321,259 | $0.00 | $0.00 |
| Feb 6, 2026 | Farquhar John C.M. | Chief Executive Officer | F | 1,541 | $27.74 | $42.7K |
| Feb 6, 2026 | Farquhar John C.M. | Chief Executive Officer | A | 183,850 | $0.00 | $0.00 |
| Feb 6, 2026 | Verghese Vikram | Chief Financial Officer | A | 119,685 | $0.00 | $0.00 |
| Feb 6, 2026 | Verghese Vikram | Chief Financial Officer | A | 68,493 | $0.00 | $0.00 |
| Feb 6, 2026 | Verghese Vikram | Chief Financial Officer | F | 542 | $27.74 | $15.0K |
| Feb 6, 2026 | Rogers Campbell | Chief Medical Officer | A | 94,488 | $0.00 | $0.00 |
| Feb 6, 2026 | Rogers Campbell | Chief Medical Officer | A | 54,073 | $0.00 | $0.00 |
| Feb 6, 2026 | Rogers Campbell | Chief Medical Officer | F | 515 | $27.74 | $14.3K |
| Feb 6, 2026 | Jones Marie L. | Chief Accounting Officer, VP | A | 37,795 | $0.00 | $0.00 |
| Feb 6, 2026 | Jones Marie L. | Chief Accounting Officer, VP | A | 21,629 | $0.00 | $0.00 |
| Feb 6, 2026 | Jones Marie L. | Chief Accounting Officer, VP | F | 94 | $27.74 | $2.6K |
| Feb 5, 2026 | Cullivan Julie A | Director | SELL | 8,000 | $27.32 | $218.6K |
| Feb 4, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | SELL | 2,000,000 | $28.05 | $56.1M |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 1 mixed, 3 neutral. Avg impact: 4.4/10.
MIXED
CLUSTER
5/10
Heartflow's CMO and CEO sold a combined $918K in open-market sales within a week of the company's st
May 20, 2026
BULLISH
8-K
7/10
Heartflow reported Q1 2026 revenue of $52.6M (+41% YoY), beating the $49.7M consensus, and raised fu
May 14, 2026
BULLISH
PRESS-RELEASE
7/10
Heartflow reported Q1 2026 revenue of $52.6M (+41% YoY), beating the $49.7M consensus, and non-GAAP
May 14, 2026
NEUTRAL
DEFA14A
2/10
Heartflow filed a DEFA14A notice of annual meeting scheduled for June 16, 2026. The board recommends
Apr 29, 2026
NEUTRAL
PRESS-RELEASE
2/10
Heartflow announced an upcoming earnings release for Q1 2026, scheduled for May 14, 2026, with no fi
Apr 23, 2026
NEUTRAL
CLUSTER
2/10
A director-affiliated entity, HealthCor Partners Management LP, reported a non-cash transaction invo
Mar 26, 2026
BEARISH
CLUSTER
6/10
Heartflow CMO Rogers Campbell sold $1.66M in open-market transactions following the exercise of deri
Mar 23, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 4 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$37.00 mean target
+29.1% upside
Strong Buy (1.57)
$35.00 Low
$40.00 High
| Metric | Value |
|---|---|
| Current Price | $28.67 |
| Target Low | $35.00 |
| Target Mean | $37.00 |
| Target Median | $37.00 |
| Target High | $40.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.57) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.13 | $-0.15 | $-0.12 | 87.7% | +0.4% | 3↑ 1↓ | $0.1B | 31.1% | 7 |
| Next Q 2026-09-30 |
$-0.11 | $-0.13 | $-0.09 | 59.1% | -2.7% | 1↑ 2↓ | $0.1B | 28.0% | 7 |
| Current FY 2026-12-31 |
$-0.49 | $-0.55 | $-0.45 | 69.7% | +4.8% | 3↑ 0↓ | $0.2B | 30.6% | 7 |
| Next FY 2027-12-31 |
$-0.26 | $-0.45 | $-0.07 | 46.1% | +11.9% | 1↑ 2↓ | $0.3B | 23.2% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.135 | |
| 7d ago | $-0.135 | |
| 30d ago | $-0.135 | +0.000 |
| 60d ago | $-0.135 | +0.000 |
| 90d ago | $-0.123 | -0.011 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 15, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 4, 2026 | William Blair | INITIATE | — | Outperform |
| Mar 19, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 19, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 9, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | Wells Fargo | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Jan 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 15, 2026
short_volume
Short Volume: HTFL — 63.6% short (0.6M / 0.9M)
Short: 599,174 | Exempt: 12,591 | TRF Vol: 941,767 | Short Ratio: 63.6% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
<p align="justify">SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coron
May 14, 2026
earnings_calendar
HTFL Q1 2026 Earnings Scheduled — 2026-05-14
Apr 27, 2026
short_interest
FTD: HTFL — 18,903 shares ($0.6M) failed to deliver
Settlement: 20260427, Price: $30.44, FTD Value: $575,407.32, HEARTFLOW INC COM
Apr 23, 2026
earnings
Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026
<p>SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery dis
Apr 16, 2026
short_interest
FTD: HTFL — 134,785 shares ($3.9M) failed to deliver
Settlement: 20260416, Price: $29.23, FTD Value: $3,939,765.55, HEARTFLOW INC COM
Apr 13, 2026
other
Heartflow Files Patent Infringement Lawsuit Against Cleerly
Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform <pre>Heartflow asserts that Cleerly infrin
Apr 7, 2026
short_interest
FTD: HTFL — 94,604 shares ($2.5M) failed to deliver
Settlement: 20260407, Price: $25.96, FTD Value: $2,455,919.84, HEARTFLOW INC COM
Mar 27, 2026
short_volume
Short Volume: HTFL — 56.8% short (0.3M / 0.6M)
Short: 337,023 | Exempt: 0 | TRF Vol: 593,657 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
short_interest
FTD: HTFL — 81,614 shares ($2.3M) failed to deliver
Settlement: 20260326, Price: $27.75, FTD Value: $2,264,788.5, HEARTFLOW INC COM
Mar 25, 2026
short_volume
Short Volume: HTFL — 57.2% short (0.3M / 0.6M)
Short: 335,784 | Exempt: 67,973 | TRF Vol: 587,300 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
short_interest
FTD: HTFL — 260,400 shares ($7.0M) failed to deliver
Settlement: 20260324, Price: $26.82, FTD Value: $6,983,928, HEARTFLOW INC COM
Mar 23, 2026
short_interest
FTD: HTFL — 26,266 shares ($0.7M) failed to deliver
Settlement: 20260323, Price: $26.02, FTD Value: $683,441.32, HEARTFLOW INC COM
Mar 18, 2026
earnings
Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results
<p align="left">MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology fo
Mar 18, 2026
earnings_calendar
HTFL Q4 2025 Earnings Scheduled — 2026-03-18